Profund Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Profund Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.09M	Sell	41,655 -40,088	-49%	-$934K	0.03%	326
2026 Q1	$1.93M	Buy	81,743 +17,572	+27%	+$448K	0.07%	218
2025 Q4	$1.86M	Buy	64,171 +31,615	+97%	+$809K	0.06%	230
2025 Q3	$614K	Sell	32,556 -113	-0.3%	-$1.78K	0.02%	446
2025 Q2	$458K	Sell	32,669 -1,069	-3%	-$15K	0.02%	489
2025 Q1	$528K	Sell	33,738 -7,285	-18%	-$103K	0.02%	454
2024 Q4	$571K	Sell	41,023 -13,559	-25%	-$149K	0.02%	446
2024 Q3	$508K	Buy	54,582 +6,392	+13%	+$63.1K	0.02%	525
2024 Q2	$448K	Sell	48,190 -78,093	-62%	-$706K	0.02%	537
2024 Q1	$1.25M	Buy	+126,283	New	+$942K	0.05%	299
2023 Q4	–	Sell	-69,926	Closed	-$371K	–	1133
2023 Q3	$371K	Sell	69,926 -19,854	-22%	-$169K	0.02%	562
2023 Q2	$856K	Buy	89,780 +33,590	+60%	+$373K	0.05%	350
2023 Q1	$618K	Buy	+56,190	New	+$813K	0.04%	441

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Profund Advisors's ARQT Position: Q2 2026 in Review

Profund Advisors reduced its Arcutis Biotherapeutics (ARQT) stake by 49% in Q2 2026, selling an estimated $934K and leaving 41,655 shares worth $1.09M. The position accounts for 0.03% of the portfolio, ranked #326.

Profund Advisors first reported a position in ARQT in Q1 2023 and has held it in 13 quarters since. The position peaked at $1.93M in Q1 2026. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Profund Advisors held 41,655 shares of Arcutis Biotherapeutics worth $1.09M as of Q2 2026.
Profund Advisors sold 40,088 Arcutis Biotherapeutics shares in Q2 2026, an estimated $934K.
Arcutis Biotherapeutics made up 0.03% of Profund Advisors's portfolio in Q2 2026, its #326 holding.
Profund Advisors first reported a position in Arcutis Biotherapeutics in Q1 2023 and has held it in 13 quarters since.
Profund Advisors's Arcutis Biotherapeutics position peaked at $1.93M in Q1 2026.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.